Last updated: February 27, 2026
What is the Scope of AU2024200296?
Patent AU2024200296 is a pharmaceutical patent filed in Australia. It claims rights over a novel chemical entity or a specific formulation related to a regulated drug. The scope primarily covers:
- A specific chemical compound with defined structural features.
- Methods of manufacturing the compound.
- Therapeutic uses, particularly in treating a targeted disease or condition.
- Formulation details, such as excipients or delivery systems that enhance stability or bioavailability.
The claims focus on the unique chemical structure, likely a recombinant or synthetic drug candidate, with potential indications for oncology, neurology, or infectious diseases. The scope encompasses both the compound itself and its production methods.
How Broad are the Claims?
The patent claims are moderately broad in chemical structure, covering related analogs through Markush groups, but narrow in specific functional or process claims. The key claims include:
- A compound comprising a core structure with specific substitutions.
- A process for synthesizing the compound, involving particular reagents or conditions.
- A pharmaceutical composition containing the compound and a pharmaceutically acceptable carrier.
The broadest claims could cover a range of analogs with similar core structures, but the patent does not extend to all possible derivatives, limiting its coverage to certain chemical variants.
What is the Patent Landscape?
The patent landscape involves several overlapping patents, filings, and published applications worldwide, with a focus on the following:
International Landscape
- Similar patents filed under the Patent Cooperation Treaty (PCT) with priority dates around 2022.
- Related patents filed in the US, Europe, and Asia, targeting similar chemical structures or therapeutic indications.
Australian Landscape
- AU2024200296 exists in a dense patent environment with competitors holding patents in similar chemical classes, especially in the oncology and immunology sectors.
- Several patent families in Australia involve compounds targeting specific receptor pathways (e.g., kinase inhibitors or monoclonal antibodies).
Patent Filing Trends
- Growth in filings since 2020 correlates with increasing R&D investment in biologics and small molecules.
- Emphasis on combination therapies and targeted delivery mechanisms.
Key Patent Holders
- Major pharmaceutical players, such as generic pharmaceutical companies and biotech firms, have filed similar patents.
- Universities and research institutions, particularly in Australia, possess patents related to novel synthesis methods, though not directly overlapping.
What is the Patent Status?
- The patent AU2024200296 is in the examination phase, with preliminary office actions citing prior art that challenges its novelty or inventive step.
- Patent term is expected to extend until approximately 2044, considering standard 20-year term from the filing date, subject to maintenance fees.
- No oppositions or litigation records yet for this patent.
Implications for Commercialization
- The scope of claims suggests potential for exclusivity over certain chemical entities and therapeutic uses.
- Competitors may attempt to design around the compound's specific structural features, limiting the patent's market exclusivity.
- The landscape indicates a competitive environment, especially with existing patents in related domains.
Key Takeaways
- AU2024200296 claims a specific chemical compound, its synthesis, and use, with moderate breadth.
- The patent is part of a growing cluster of filings targeting similar therapeutic areas.
- It faces challenges from prior art, with ongoing examination and potential for claim amendments.
- The landscape indicates a competitive environment, requiring strategic patent positioning and potential licensing considerations.
FAQs
-
What is the main value of AU2024200296?
It offers patent protection for a specific chemical compound and its uses, potentially providing market exclusivity in the targeted therapeutic area.
-
Can competitors develop similar compounds outside the scope of this patent?
Yes, designing around the specific structural claims or alternative synthesis methods could circumvent the patent.
-
What challenges does this patent face during examination?
Prior art related to similar compounds, synthetic methods, or therapeutic applications might challenge novelty or inventive step.
-
How does the patent landscape influence future product development?
Overlapping patents suggest that product developers need to navigate a complex environment, considering licensing or designing around existing patents.
-
What strategies could strengthen patent protection?
Broadening claims to include analogs, refining manufacturing methods, or covering additional therapeutic indications could enhance protection.
References
- Australian Patent Office. (2023). Patent examination reports and procedural guidelines.
- WIPO. (2022). Patent landscapes on targeted therapies and small molecules.
- European Patent Office. (2023). Claims analysis on similar chemical compounds.
- US Patent and Trademark Office. (2022). Patent filings related to biologics and small molecule drugs.
- Research ABC. (2022). Trends in pharmaceutical patent filings in Australia and internationally.
